Repatha dosage
Pro Research Analysisby 
Searched over 200M research papers for "repatha dosage"
Consensus Meter
Repatha Dosage: An Overview
Introduction to Repatha (Evolocumab)
Repatha, also known by its generic name evolocumab, is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This medication is primarily used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients with hyperlipidemia, including those with familial hypercholesterolemia .
Dosage Recommendations for Repatha
Standard Dosage
Repatha is administered via subcutaneous injection. The standard dosage for Repatha is either 140 mg every two weeks or 420 mg once a month . This flexibility in dosing allows for patient convenience and adherence to the treatment regimen.
Dosage in Clinical Trials
In various clinical trials, Repatha has been shown to significantly reduce LDL-C levels. For instance, in 12-week phase III trials, evolocumab reduced LDL-C levels by 54.8% to 76.3% compared to placebo and by 36.9% to 47.2% compared to ezetimibe. These trials included patients with primary hypercholesterolemia, mixed dyslipidemia, and both heterozygous and homozygous familial hypercholesterolemia.
Efficacy of Repatha
LDL-C Reduction
Repatha has demonstrated a substantial reduction in LDL-C levels. When added to statin therapy, it can lower LDL-C by up to 60% from baseline . This reduction is also observed in patients who are statin-intolerant or those who are on monotherapy.
Additional Lipid Parameters
Beyond LDL-C, Repatha also significantly reduces total cholesterol, non-HDL cholesterol, apoprotein B, and lipoprotein(a). These reductions contribute to its overall efficacy in managing hyperlipidemia.
Safety and Tolerability
Repatha has been well-tolerated in clinical trials, with a safety profile comparable to placebo and other lipid-lowering therapies . The long-term safety and efficacy of Repatha are still under investigation, but current data suggest it is a safe option for patients needing additional LDL-C reduction.
Conclusion
Repatha (evolocumab) is a potent PCSK9 inhibitor that offers significant LDL-C reduction for patients with hyperlipidemia, including those with familial hypercholesterolemia. Administered at a dosage of 140 mg every two weeks or 420 mg once a month, it provides flexibility and convenience for patients. Clinical trials have demonstrated its efficacy and safety, making it a valuable option for those who cannot achieve LDL-C goals with statins alone or who are statin-intolerant.
Sources and full results
Most relevant research papers on this topic